Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Tangible Book Value Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Work In Process

Daily Values

Growth Metrics

Others

China Pharma Holdings (CPHI) Convertible Debt (2021 - 2022)

Historic Convertible Debt for China Pharma Holdings (CPHI) over the last 2 years, with Q2 2022 value amounting to $4.8 million.

China Pharma Holdings' Convertible Debt changed N/A to $4.8 million in Q2 2022 from the same period last year, while for Jun 2022 it was $4.8 million, marking a year-over-year change of. This contributed to the annual value of $5.2 million for FY2021, which is N/A changed from last year.
Latest data reveals that China Pharma Holdings reported Convertible Debt of $4.8 million as of Q2 2022.
In the past 5 years, China Pharma Holdings' Convertible Debt ranged from a high of $5.2 million in Q4 2021 and a low of $4.8 million during Q2 2022